Form D · Biotechnology

Epicrispr Biotechnologies, Inc.

South San Francisco, CA · CIK 0002151604

Offering snapshot reported Aug 26, 2026 · SEC filing

Reported sold
$177M
Offering amount: $213M
Investors reported
47
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 4, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 26, 2026Initial$176,754,406No comparison47SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-595347
Series Seed Preferred: $2,499,999.60; Series A-1 Preferred: $51,449,986.60; Series B Preferred: $58,055,021.19; Series B warrants: $1,225.78; Series B-1 Preferred: $10,750,000; Series C Preferred: $53,999,398.66; Series C warrants: $35,999,598.70.

Source: Form D, filed Aug 26, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Eric Crombez Director
Jennifer King Director
Andrew Lam Director
Anran Li Director
Lei Qi Director
Amber Salzman Director, Executive
Haorui Zhang Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
7000 Shoreline Court, Ste 100
South San Francisco, CA, 94080
Phone: 510-934-7574